Michael Iskedjian

Michael Iskedjian

Auto-generated profile, based on publicly available information

Michael Iskedjian

PharmIdeas USA, Williamsville, NY

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2008 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
MIMichael Iskedjian
Michael Iskedjian
JWJohn H. Walker
John H. Walker
BBBasil G. Bereza
Basil G. Bereza
JMJean‑Michel Le Melledo
Jean‑Michel Le Melledo
TEThomas R. Einarson
Thomas R. Einarson
Background: Generalized Anxiety Disorder (GAD) is a common chronic disease with a lifetime prevalence estimated to range from 4.2% to 12.7%. GAD places a sub­stantial burden upon patients and healthcare resources. Objective: To determine the cost-effectiveness of escitalopram for GAD in a Canadian primary care setting from two perspectives [Ministry of Health (MoH) and society (SOC)]. Methods: A 24-week decision-analytic model was constructed using Data/TreeAge software. Patients were treated with escitalopram or generic paroxetine. Clinical rates were determined from the literature; expert opinion guided model pathway development. Effectiveness was measured as ‘symptom-free days’ (SFDs). Analyses from MoH perspective focused on direct costs of treatment (drugs, physician visits), while SOC also accounted for indirect costs associated with workdays lost due to GAD. Unit costs of healthcare services and wage rates were obtained from standard Canadian sources (2005 Canadian $ values). Cost-effectiveness was expressed as the incremental cost-effectiveness ratio (ICER). Extensive one-way and probabilistic sensitivity analyses were conducted. Results: Escitalopram was associated with higher expected number of SFDs than paroxetine (86.4 vs. 77.0 SFD, respectively). From the MoH perspective, expected costs were Can$724 and Can$663 for escitalopram and paroxetine arms, respectively, resulting in the ICER for escitalopram vs. paroxetine of Can$6.56/SFD (Can$2362/symptom-free year). From the SOC perspective, escitalopram dominated paroxetine as more effective on SFDs and less costly. Sensitivity analyses demonstrated robustness of the model. Limitations include the absence of comorbidities, which are common in practice, lack of long-term data, and assuming that dropouts in trials reflect those in practice. Conclusion: Escitalopram was found to be cost-effective compared with paroxetine in treatment of GAD from the Canadian MoH perspective, and dominating paroxetine from the SOC perspective. Therefore, a possible advantage may exist at the population level in the treatment of GAD with escitalopram in Canada.

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
MIMichael Iskedjian
Michael Iskedjian
EVEdward Bentz De Vol
Edward Bentz De Vol
MEMahmoud Elshenawy
Mahmoud Elshenawy
SBShouki Bazarbashi
Shouki Bazarbashi
PURPOSE: Health utilities (HUs) are quantitative measures of quality of life that are used to derive outcomes such as quality-adjusted life years in cost-effectiveness analyses. In the Kingdom of Saudi Arabia, there are no HUs for cancer. This study aimed to generate HU estimates for various health states associated with cancer in the Kingdom of Saudi Arabia.METHODS: Adult citizens of the Kingdom of Saudi Arabia, patients with cancer, and patients without cancer were recruited to participate in an online version of the Time Trade-Off (TTO) survey, a direct method that asks participants to indicate the amount of time they are willing to trade off in return for full health. The time horizon was 10 years. Patients were surveyed on their own health state; patients without cancer were presented with a scenario describing stage III colon cancer and were asked to act as proxies.RESULTS: Mean HU score was 0.398 (n = 398), 0.315 for patients with cancer (n = 199), and 0.482 for patients without cancer (n = 199). Among patients, the largest subgroup with colorectal cancer (n = 105), had a mean HU of 0.296; the subgroup with the lowest mean HU was patients with hepatocellular cancer (n = 3; 0.047), and the subgroup with the highest mean HU was patients with cholangiocarcinoma (n = 5; 0.508). Overall, the initial stage I subgroup (n = 7) had a mean HU of 0.456; initial stage II (n = 25), 0.240; stage II (n = 67), 0.319; and initial stage IV (n = 77), 0.320.CONCLUSION: To our knowledge, this is the first study of this size to elicit HU scores for cancer in the Kingdom of Saudi Arabia. Patients may have had clinically worse disease than the patients in the scenario that was presented to patients without cancer. Further analyses are warranted for specific types of cancer. These HUs can in turn be applied in cost-utility analyses.

1 January 2007 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
TET. Einarson
T. Einarson
MMM. Machado
M. Machado
JWJ. Walker
J. Walker
MIM. Iskedjian
M. Iskedjian
PCP-Y. Cremieux
P-Y. Cremieux
PLPatrick Lefebvre
Patrick Lefebvre

3 September 2023
Verified
Preprint
Open access
PDF file
MIMichael Iskedjian
Michael Iskedjian
The paper is easy to read, scientifically sound and sufficiently detailed. However, it is more a research protocol than a research paper. This should constitute Part I: Research Protocol and Scientific Approach, and another paper should be prepared a...